Whilst the use of mGlu5 NAMs to modify disease progression in AD has been promising, disrupting glutamate signaling via the antagonism or genetic deletion of mGlu5 has deleterious effects on learning and memory independent of AD (Simonyi, Schachtman and Christoffersen, 2005). This evidence concerns the gene GRM5 and Alzheimer disease.